Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
13
Jun |
Do ‘EpiPens’ Save Lives?Category: Allergy | Leave a Comment |
Over 100,000 adrenaline auto-injectors (’EpiPen’) have been given to people with severe food allergy (food anaphylaxis) over the past 20 years, but as the death rate has remained at around five per year it seems possible they are not saving lives. New research from Dr Richard Pumphrey of the Central Manchester Hospitals, UK, has today revealed why…
|
22
Sep |
Greenway Introduces New Advanced Allergy Module For PrimeSuite EHRCategory: Allergy | Leave a Comment |
Greenway Medical Technologies, Inc. announced the most advanced allergy module available in an integrated electronic health record (EHR) solution for ear, nose and throat (ENT) and allergy physician practices…
|
24
May |
Improving Diagnosis And Detection Of Food AllergiesCategory: Allergy | Leave a Comment |
About 30 percent of Americans believe they have food allergies. However, the actual number is far smaller, closer to 5 percent, according to a recent study commissioned by the National Institute of Allergy and Infectious Diseases (NIAID). That’s due in large part to the unreliability of the skin test that doctors commonly use to test for food allergies…
|
22
Mar |
Television Star Alison Sweeney Joins ZYRTEC(R) To Welcome The Arrival Of Spring With The ‘Race Against Your Allergies’Category: Allergy | Leave a Comment |
Allergy sufferer and actress Alison Sweeney joined the makers of the fastest 24-hour over-the-counter (OTC) allergy medicine, ZYRTEC®,for an unusual race to officially welcome the first day of spring and new ZYRTEC® Liquid Gels…
|
11
Nov |
Phadia Introduces New Food Allergy Diagnostic Tools To Meet The Needs Of AllergistsCategory: Allergy | Leave a Comment |
Today at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology, Phadia US introduced two new products designed specifically to meet the unique needs of the nation’s 6,000 allergists. ImmunoCAP ISAC and ImmunoCAP HR are new offerings designed to augment traditional allergy testing methodologies and enable diagnosis of complex food allergies at the molecular level, available through its own PiRL testing facility.
|
29
Oct |
Dey Launches And Unveils Next-Generation, Needle-Protected EpiPen(R) (Epinephrine) Auto-Injector With Enhanced Patient-Friendly FeaturesCategory: Allergy | Leave a Comment |
Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL - News), launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use. Dey President Carolyn Myers, Ph.D.
|
27
Nov |
Da Vinci Award For Allergy Lab TestCategory: Allergy | Leave a Comment |
Scientists who have developed a new technique that can test for up to 5,000 different allergens from just one drop of blood have scooped a prestigious national award which encourages innovation in healthcare technologies. The new basophil-microarray based allergy assay is the brainchild of researchers in The University of Nottingham’s Schools of Pharmacy and Biosciences, in collaboration with colleagues in the Centre for Respiratory Research at Nottingham City Hospital.